How have SMMT shares performed in 2023?

Summit Therapeutics' stock was trading at $4.25 at the start of the year. Since then, SMMT shares have decreased by 49.9% and is now trading at $2.13. View the best growth stocks for 2023 here .

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our SMMT earnings forecast .

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $0.27 million during the quarter.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET) , Summit Therapeutics (SUMM) , Sarepta Therapeutics (SRPT) , Gilead Sciences (GILD) , CBL & Associates Properties (CBL) , SandRidge Permian Trust (PER) , Cornerstone Total Return Fund (CRF) , Ford Motor (F) and Martin Midstream Partners (MMLP) .

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.15%), Charles Schwab Investment Management Inc. (0.13%), Shell Asset Management Co. (0.05%), California State Teachers Retirement System (0.02%), Barclays PLC (0.02%) and Rhumbline Advisers (0.02%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh , Manmeet Singh Soni and Robert W Duggan . View institutional ownership trends .

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Summit Therapeutics Stock Price, News & Analysis (NASDAQ:SMMT)

$2.13

+0.10 (+4.93%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.93
▼
$2.14
50-Day Range: $1.67
▼
$2.18
52-Week Range: $0.66
▼
$5.78

Volume: 1.70 million shs
Average Volume: 935,375 shs
Market Capitalization: $1.49 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Summit Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
1.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.28
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$5 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.21 out of 5 stars

Medical Sector

919th out of 952 stocks

Pharmaceutical Preparations Industry

431st out of 445 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Summit Therapeutics.

1.0

Short Interest

Percentage of Shares Shorted
1.43% of the outstanding shares of Summit Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Summit Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Summit Therapeutics has recently increased by 5.49%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Summit Therapeutics does not currently pay a dividend.
Dividend Growth
Summit Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SMMT.

2.9

News and Social Media Coverage

News Sentiment
Summit Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Summit Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 10 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 5.01% of the stock of Summit Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Summit Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Summit Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Summit Therapeutics has a P/B Ratio of 15.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Summit Therapeutics Stock (NASDAQ:SMMT)

Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.

SMMT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SMMT Stock News Headlines

November 26, 2023 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $1.95

November 7, 2023 | finance.yahoo.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 7, 2023 | finance.yahoo.com

Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational Progress

November 2, 2023 | finance.yahoo.com

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

November 1, 2023 | bizjournals.com

Former Reata Pharmaceuticals CFO steps into new role with California biotech company

October 31, 2023 | finance.yahoo.com

Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

October 26, 2023 | finance.yahoo.com

Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 19, 2023 | finance.yahoo.com

H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development

October 17, 2023 | finance.yahoo.com

Insider Buying: COO Manmeet Soni Acquires 2,976,190 Shares of Summit Therapeutics Inc

September 26, 2023 | msn.com

Summit Therapeutics: Not For Retail Investors

September 25, 2023 | seekingalpha.com

Navigating Summit Therapeutics' Bispecific Bet Amid Cash Constraints

August 9, 2023 | finance.yahoo.com

Q2 2023 Summit Therapeutics Inc Earnings Call

August 9, 2023 | seekingalpha.com

Summit Therapeutics, Inc. (SMMT) Q2 2023 Earnings Call Transcript

August 9, 2023 | finance.yahoo.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

August 2, 2023 | finance.yahoo.com

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

July 11, 2023 | finance.yahoo.com

Summit Therapeutics Insiders Up US$558m On US$517m Investment

June 4, 2023 | finance.yahoo.com

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

June 1, 2023 | finance.yahoo.com

Ivonescimab Updated Data to be Featured at ASCO 2023

May 22, 2023 | finance.yahoo.com

11 Stocks with Heavy Insider Buying in 2023

May 18, 2023 | finance.yahoo.com

After buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2b

May 16, 2023 | finance.yahoo.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call Transcript

May 16, 2023 | finance.yahoo.com

Why Shares of Summit Therapeutics Slumped on Tuesday

May 12, 2023 | finance.yahoo.com

Q1 2023 Summit Therapeutics Inc Earnings Call

May 11, 2023 | seekingalpha.com

Summit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call Transcript

May 11, 2023 | finance.yahoo.com

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

See More Headlines

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SMMT
CUSIP: N/A
CIK: 1599298
Web: www.summitplc.com
Phone: 650-460-8308
Fax: 44-12-3544-3999
Employees: 76
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-78,780,000.00
Net Margins: N/A
Pretax Margin: -271,685.00%
Return on Equity: -64.01%
Return on Assets: -22.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.80
Quick Ratio: 1.80

Sales & Book Value

Annual Sales: $700,000.00
Price / Sales: 2,132.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.14 per share
Price / Book: 15.21

Miscellaneous

Outstanding Shares: 700,840,000
Free Float: 114,237,000
Market Cap: $1.49 billion
Optionable: Optionable
Beta: -0.97

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Robert W. Duggan (Age 79)
Co-CEO & Executive Chairman
Dr. Mahkam Zanganeh D.D.S. (Age 53)
M.B.A., Co-CEO, President & Director
Comp: $934.85k
Mr. Ankur Dhingra (Age 47)
Chief Financial Officer
Comp: $668.39k
Mr. Manmeet Singh Soni (Age 45)
COO & Director
Dr. Urte Gayko Ph.D. (Age 52)
Chief Regulatory, Quality & Pharmacovigilance Officer?
Prof. Dame Kay Davies DBE (Age 72)
FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Ms. Shelley D. Spray (Age 58)
Head of Corporate Education, Communications & Creative?
Ms. Abby Guzman Murphy
Head of Human Resources
Ms. Divya Chari (Age 55)
Head of Global Clinical Operations
Mr. Dave Gancarz
Chief Business & Strategy Officer?

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SMMT Stock Analysis - Frequently Asked Questions

How have SMMT shares performed in 2023?: Summit Therapeutics' stock was trading at $4.25 at the start of the year. Since then, SMMT shares have decreased by 49.9% and is now trading at $2.13.
View the best growth stocks for 2023 here.
When is Summit Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our SMMT earnings forecast.
How were Summit Therapeutics' earnings last quarter?: Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $0.27 million during the quarter.
What ETFs hold Summit Therapeutics' stock?: ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Summit Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).
When did Summit Therapeutics IPO?: (SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.
Who are Summit Therapeutics' major shareholders?: Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.15%), Charles Schwab Investment Management Inc. (0.13%), Shell Asset Management Co. (0.05%), California State Teachers Retirement System (0.02%), Barclays PLC (0.02%) and Rhumbline Advisers (0.02%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan.
View institutional ownership trends.
How do I buy shares of Summit Therapeutics?: Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SMMT) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial